Drugs / ReCOV
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04818801 | Jun 2021 → May 2022 | COVID-19 | Jiangsu Rec-Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05084989 | Jan → Aug 2022 | COVID-19 | Jiangsu Rec-Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT05679466 Comparator | Dec 2022 → Jun 2023 | COVID-19 | Yu Qin | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ReCOV | “The recombinant two-component COVID-19 vaccine (CHO cell) developed and produced by Jiangsu Recbio Biotechnology Co., LTD. ( Recbio ), referred to as "ReCOV", is a new...” NCT05679466 ↗1“INTRODUCTION: ReCOV is a recombinant protein vaccine that aims to induce cross-neutralization against SARS-CoV-2 variants.” PMID 38103161 ↗ Dec 2023 |
| Modality | Vaccine | “ReCOV is a recombinant protein vaccine” PMID 38103161 ↗ Dec 2023 |
| Route | Intramuscular | “intramuscular injection” NCT04818801 ↗ |